Outcomes from second-line therapy in long-term responders to first-line tyrosine kinase inhibitor in clear-cell metastatic renal cell carcinoma.
about
Axitinib after Sunitinib in Metastatic Renal Cancer: Preliminary Results from Italian "Real-World" SAX Study.Targeted therapy for renal cell carcinoma: focus on 2nd and 3rd line.Current Clinical Practice Guidelines for the Treatment of Renal Cell Carcinoma: A Systematic Review and Critical Evaluation.
P2860
Outcomes from second-line therapy in long-term responders to first-line tyrosine kinase inhibitor in clear-cell metastatic renal cell carcinoma.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Outcomes from second-line ther ...... tastatic renal cell carcinoma.
@en
type
label
Outcomes from second-line ther ...... tastatic renal cell carcinoma.
@en
prefLabel
Outcomes from second-line ther ...... tastatic renal cell carcinoma.
@en
P2093
P2860
P50
P356
P1433
P1476
Outcomes from second-line ther ...... etastatic renal cell carcinoma
@en
P2093
A Harbaoui
C Linassier
E De Guillebon
J-C Eymard
M Aitelhaj
M Gross-Goupil
P2860
P304
P356
10.1093/ANNONC/MDU552
P577
2014-12-01T00:00:00Z